Given the complex relationship between insulin therapy, adiposity, and cardiovascular risk in T1D, AOMs may offer a promising adjunctive strategy—particularly if introduced early, during or shortly after the honeymoon phase, when metabolic trajectories may still be modifiable. The gene discussed is INS; the disease is type 1 diabetes mellitus.